Fig. 10

Seeking potential therapeutic agents for the high LRGS group. A Schematic outlining the strategy to develop potential therapeutic agents with higher drug sensitivity in the high risk group. B The results of Spearman’s correlation analysis and differential drug response analysis of three CTRP-derived compounds. C The results of Spearman’s correlation analysis and differential drug response analysis of ten PRISM-derived compounds. Lower AUC values imply greater sensitivity. D-G. The differences of sensitivity of patients to cisplatin (D), Gemcitabine (E), paclitaxel (F) and Gefitnib (G). Lower IC50 is equal to better sensitivity. H Scatter plot illustrating spearman’s correlations and significance between the 23 model genes and chemotherapeutic drugs using data from the CCLE. Statistical significance: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001